KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...

ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ...

Onapgo is a wearable pump designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). The drug is meant to allow patients more control over their daily "off" time ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

This study demonstrated that 32-G 5-mm needles can be reliably inserted into subcutaneous fat, are relatively pain free, and are associated with minimal leakage from the injection site.

Drug dosages (1.0, 2.5, 5.0, and 10.0 mg/ mL) and pump infusion rates are adjusted so that accurate drug delivery can be achieved with only one daily syringe change. However, the stability of ...

Apellis' C3 inhibitor Empaveli (pegcetacoplan) is also approved for PNH, and is given by subcutaneous infusion, but remains a relatively minor product with sales of less than $25 million in the ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The team used 48 Angus-cross feedyard steers, with each receiving two different subcutaneous injection treatments to either side of the neck. The researchers compared injections using: An ...